Knight Therapeutics - GUD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$6.58
  • Forecasted Upside: 14.29%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
C$5.76
▲ +0.06 (1.05%)

This chart shows the closing price for GUD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Knight Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GUD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GUD

Analyst Price Target is C$6.58
▲ +14.29% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is C$6.58, with a high forecast of C$7.50 and a low forecast of C$5.25. The average price target represents a 14.29% upside from the last price of C$5.76.

This chart shows the closing price for GUD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Knight Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/22/2024Royal Bank of CanadaBoost TargetOutperformC$6.50 ➝ C$7.00
3/6/2024Raymond JamesBoost TargetOutperformC$7.00 ➝ C$7.50
2/28/2024Raymond JamesSet TargetOutperformC$7.00
11/10/2023Stifel NicolausLower TargetC$5.40 ➝ C$5.25
3/24/2023National Bank FinancialDowngradeOutperform Market Weight ➝ Sector Perform Market Weight
3/24/2023National BanksharesLower TargetOutperform ➝ Sector PerformC$7.75 ➝ C$6.00
3/24/2023Royal Bank of CanadaLower TargetOutperformC$7.50 ➝ C$6.50
8/12/2022Stifel NicolausBoost TargetC$5.30 ➝ C$5.40
8/12/2022National BanksharesBoost TargetOutperformC$7.50 ➝ C$7.75
4/1/2022Raymond JamesSet TargetOutperformC$7.50
3/28/2022Bloom BurtonReiterated RatingBuyC$6.70
3/25/2022Bloom BurtonDowngradeBuy ➝ Accumulate
3/25/2022National Bank FinancialLower TargetOutperformC$8.00 ➝ C$7.50
3/25/2022Raymond JamesLower TargetOutperformC$8.50 ➝ C$7.50
3/25/2022Canaccord Genuity GroupLower TargetC$8.00 ➝ C$7.00
3/25/2022National BanksharesLower TargetOutperformC$8.00 ➝ C$7.50
3/24/2022Stifel NicolausDowngradeHoldC$5.30
11/12/2021Raymond JamesSet TargetOutperformC$8.50
11/12/2021National BanksharesBoost TargetOutperformC$7.75 ➝ C$8.00
9/24/2021Raymond JamesReiterated RatingOUTPERFORMC$8.50
9/22/2021Stifel NicolausUpgradeBuyC$6.50
8/17/2021Raymond JamesReiterated RatingOutperformC$8.50
7/13/2021Royal Bank of CanadaReiterated RatingOutperformC$7.50
5/17/2021Raymond JamesReiterated RatingOutperformC$8.50
4/26/2021National Bank FinancialBoost TargetOutperformC$7.75
4/26/2021National BanksharesBoost TargetOutperformC$6.75 ➝ C$7.75
4/26/2021Raymond JamesBoost TargetOutperformC$8.00 ➝ C$8.50
3/26/2021Bloom BurtonUpgradeAccumulate ➝ Buy
3/26/2021Raymond JamesReiterated RatingOutperformC$8.00
3/25/2021National Bank FinancialReiterated RatingOutperform Market Weight
11/16/2020National Bank FinancialLower TargetOutperformC$8.25 ➝ C$6.75
11/16/2020Raymond JamesLower TargetOutperformC$10.25 ➝ C$8.00
11/16/2020Royal Bank of CanadaLower TargetOutperformC$8.00 ➝ C$7.50
9/23/2020Raymond JamesSet TargetOutperformC$10.25
8/27/2020Royal Bank of CanadaLower TargetOutperformC$9.50 ➝ C$8.00
8/26/2020Raymond JamesSet TargetOutperformC$10.25
8/17/2020Raymond JamesSet TargetOutperformC$10.25
6/29/2020Bloom BurtonDowngradeBuy ➝ Accumulate
6/29/2020National Bank FinancialLower TargetOutperformC$8.75 ➝ C$8.25
6/29/2020Raymond JamesSet TargetOutperformC$10.25
5/4/2020National Bank FinancialLower TargetOutperformC$9.00 ➝ C$8.75
4/20/2020Raymond JamesSet TargetOutperformC$10.25
4/1/2020Raymond JamesSet TargetOutperformC$10.25
3/31/2020National Bank FinancialLower TargetOutperformC$9.25 ➝ C$9.00
3/5/2020National Bank FinancialLower TargetC$10.00 ➝ C$9.25
1/9/2020Raymond JamesSet TargetOutperformC$10.25
11/22/2019Raymond JamesSet TargetOutperformC$10.25
11/13/2019Raymond JamesReiterated RatingOutperformC$10.25
10/22/2019Bloom BurtonUpgradeAccumulate ➝ Buy
10/22/2019Raymond JamesSet TargetOutperformC$10.25
10/22/2019National Bank FinancialBoost TargetOutperformC$9.50 ➝ C$10.00
10/9/2019Raymond JamesReiterated RatingOutperformC$10.25
8/9/2019Raymond JamesSet TargetOutperformC$10.25
7/18/2019Raymond JamesReiterated RatingOutperformC$10.25
5/8/2019Raymond JamesReiterated RatingOutperformC$10.25
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.86 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/17/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/16/2024

Current Sentiment

  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Knight Therapeutics logo
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: C$5.76
Low: C$5.72
High: C$5.88

50 Day Range

MA: C$5.47
Low: C$5.23
High: C$5.87

52 Week Range

Now: C$5.76
Low: C$4.35
High: C$5.95

Volume

69,330 shs

Average Volume

76,605 shs

Market Capitalization

C$582.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Knight Therapeutics?

The following Wall Street sell-side analysts have issued reports on Knight Therapeutics in the last twelve months: Raymond James, Royal Bank of Canada, and Stifel Nicolaus.
View the latest analyst ratings for GUD.

What is the current price target for Knight Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Knight Therapeutics in the last year. Their average twelve-month price target is C$6.58, suggesting a possible upside of 14.3%. Raymond James has the highest price target set, predicting GUD will reach C$7.50 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of C$5.25 for Knight Therapeutics in the next year.
View the latest price targets for GUD.

What is the current consensus analyst rating for Knight Therapeutics?

Knight Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GUD will outperform the market and that investors should add to their positions of Knight Therapeutics.
View the latest ratings for GUD.

What other companies compete with Knight Therapeutics?

Other companies that are similar to Knight Therapeutics include Aurora Cannabis, Organigram, Supreme Cannabis, ESSA Pharma and ICC Labs. Learn More about companies similar to Knight Therapeutics.

How do I contact Knight Therapeutics' investor relations team?

Knight Therapeutics' physical mailing address is 3400 de Maisonneuve Boulevard West, Suite 1055, Montreal, QC H3Z 3B8, Canada. The company's listed phone number is 514-484-4483. The official website for Knight Therapeutics is www.gud-knight.com. Learn More about contacing Knight Therapeutics investor relations.